See the DrugPatentWatch profile for Cotempla
Cotempla XR-ODT is a once-daily extended-release orally disintegrating tablet formulation of methylphenidate, used to treat Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older [1]. It is designed to dissolve rapidly in the mouth without the need for water [1].
How does Cotempla XR-ODT work for ADHD?
Cotempla XR-ODT contains methylphenidate, a central nervous system stimulant [1]. It works by increasing the levels of certain neurotransmitters, primarily dopamine and norepinephrine, in the brain [2]. These neurotransmitters play a crucial role in regulating attention, impulsivity, and hyperactivity [2]. By enhancing their activity, methylphenidate helps improve focus and reduce disruptive behaviors associated with ADHD [2].
What is the active ingredient in Cotempla?
The active ingredient in Cotempla XR-ODT is methylphenidate [1].
When does the patent for Cotempla expire?
Information regarding the specific patent expiry dates for Cotempla XR-ODT is available through resources like DrugPatentWatch.com, which tracks patent and exclusivity information for pharmaceuticals [3].
Who manufactures Cotempla XR-ODT?
Cotempla XR-ODT is manufactured by Neos Therapeutics [4].
What are the common side effects of Cotempla?
Common side effects associated with Cotempla XR-ODT can include decreased appetite, insomnia, weight loss, stomach pain, nausea, vomiting, and anxiety [1]. It is important to note that this is not an exhaustive list, and patients should discuss potential side effects with their healthcare provider [1].
How is Cotempla XR-ODT different from other ADHD medications?
Cotempla XR-ODT is distinguished by its extended-release formulation and its orally disintegrating tablet (ODT) form, which allows for rapid dissolution in the mouth without water [1]. This can be a convenient option for individuals who have difficulty swallowing pills [1]. Other ADHD medications may come in different forms, such as immediate-release tablets, capsules, or patches, and may contain different active ingredients or release mechanisms [2].
What clinical data supports Cotempla's effectiveness?
Clinical trials have been conducted to evaluate the safety and efficacy of Cotempla XR-ODT in treating ADHD [1]. These studies typically assess improvements in ADHD symptoms, such as inattention and hyperactivity, compared to placebo [1]. Detailed clinical trial data can often be found in the drug's prescribing information or through medical databases [1].
What are the risks associated with stimulant medications like Cotempla?
Stimulant medications, including methylphenidate, carry potential risks such as cardiovascular problems, psychiatric disorders, and the potential for abuse or dependence [1]. Healthcare providers carefully assess patients for these risks before prescribing and monitor them during treatment [1].
Can generic versions of Cotempla XR-ODT be developed?
The development and availability of generic versions of Cotempla XR-ODT depend on patent expiry and regulatory approval [3]. Once patents expire and regulatory hurdles are cleared, other manufacturers may be able to produce and market generic equivalents [3].
What are the administration instructions for Cotempla XR-ODT?
Cotempla XR-ODT should be taken once daily as prescribed by a healthcare provider [1]. The tablet is placed on the tongue and disintegrates in the mouth; it can be swallowed with or without liquid [1]. It is typically recommended to take it in the morning [1].
Sources:
[1] https://www.cotempla.com/
[2] https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
[3] https://drugpatentwatch.com/
[4] https://www.neostherapeutics.com/